Adrenocortical Carcinoma
58
11
18
21
Key Insights
Highlights
Success Rate
72% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.8%
8 terminated out of 58 trials
72.4%
-14.1% vs benchmark
5%
3 trials in Phase 3/4
29%
6 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (58)
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Familial Investigations of Childhood Cancer Predisposition
German Adrenocortical Carcinoma Registry
Adrenal Tumors - Pathogenesis and Therapy
Evaluation of Side Effects of Mitotane
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.